```
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:56:42 ON 11 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 MAR 2004  HIGHEST RN 661450-61-9
DICTIONARY FILE UPDATES:  10 MAR 2004  HIGHEST RN 661450-61-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l11
L1                STR
```




```
VAR G1=C/S/N
REP G2=(0-1) A
VAR G3=C/N/O
NODE ATTRIBUTES:
NSPEC   IS RC     AT  14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L3           269 SEA FILE=REGISTRY SSS FUL L1
L4               STR
```




VAR G1=C/17/SO2/N
REP G2=(0-1) 33
VAR G3=C/31/N/22/O
VAR G4=X/AK/O/S/20/N/22/24/26
VAR G5=X/O
VAR G6=H/AK/CB/36
VAR G7=H/AK/X/OH/44/CN/46/49
VAR G8=OH/44/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 14
CONNECT IS M1 RC AT 14
CONNECT IS M1 RC AT 33
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 46

STEREO ATTRIBUTES: NONE
L6 204 SEA FILE=REGISTRY SUB=L3 CSS FUL L4
L7 STR



VAR G1=C/17/SO2/N
VAR G3=C/31/N/22/O
VAR G4=X/AK/O/S/20/N/22/24/26
VAR G5=X/O
VAR G6=H/AK/CB/36
VAR G7=H/AK/X/OH/44/CN/46/49
VAR G8=OH/44/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 14
CONNECT IS M1 RC AT 14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE
L8 32 SEA FILE=REGISTRY SUB=L6 CSS FUL L7
L9 STR




VAR G1=C/17/SO2/N
VAR G3=C/31/N/22/O
VAR G4=X/AK/O/S/20/N/22/24/26
VAR G5=X/O
VAR G6=H/AK/CB/36
VAR G7=H/AK/X/OH/44/CN/46/49
VAR G8=OH/44/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 14
CONNECT IS M1 RC AT 14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 10
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L10 171 SEA FILE=REGISTRY SUB=L6 CSS FUL L9
L11 203 SEA FILE=REGISTRY ABB=ON PLU=ON (L8 OR L10)

=> d sta que l32
L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 12
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L18 193 SEA FILE=REGISTRY SSS FUL L16
L19 STR



VAR G1=N/27
VAR G2=H/30
VAR G3=AK/CB/34
VAR G4=X/AK/CHO/41/43
VAR G5=C/36
VAR G6=AK/CB
NODE ATTRIBUTES:

```
CONNECT IS M1  RC AT  18
CONNECT IS M1  RC AT  21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  12
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE
L21          187 SEA FILE=REGISTRY SUB=L18 CSS FUL L19
L25              STR
```




```
VAR G1=AK/CB/25/27
VAR G2=X/30/32
NODE ATTRIBUTES:
CONNECT IS M1  RC AT   7
CONNECT IS M1  RC AT   8
CONNECT IS M1  RC AT  14
CONNECT IS M1  RC AT  15
CONNECT IS M1  RC AT  16
CONNECT IS E2  RC AT  21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  12
NUMBER OF NODES IS  35

STEREO ATTRIBUTES: NONE
L27           18 SEA FILE=REGISTRY SUB=L21 CSS FUL L25
L28          169 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 NOT L27
L29           35 SEA FILE=REGISTRY ABB=ON  PLU=ON  L28 NOT SQL/FA
L30            7 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 AND (T/ELS OR 14C OR
                 C29H41N5O4 OR C26H35N5O4 OR C27H37N5O4)
L31           28 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 NOT L30
L32           46 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L27 OR L31)


=> d his

     (FILE 'HOME' ENTERED AT 13:49:45 ON 11 MAR 2004)
```

```
                SET COST OFF

     FILE 'REGISTRY' ENTERED AT 13:50:08 ON 11 MAR 2004
L1                  STR
L2               13 S L1
L3              269 S L1 FUL
                    SAV L3 VKIM929A/A
L4                  STR L1
L5               10 S L4 CSS SAM SUB=L3
L6              204 S L4 CSS FUL SUB=L3
                    SAV L6 VKIM929A1/A
L7                  STR L4
L8               32 S L7 CSS FUL SUB=L6
                    SAV L8 VKIM929A2/A
L9                  STR L7
L10             171 S L9 CSS FUL SUB=L6
                    SAV L10 VKIM929A3/A
L11             203 S L8,L10
L12              66 S L3 NOT L11
L13                 STR L1
L14              10 S L13 CSS SAM SUB=L11
L15             191 S L13 CSS FUL SUB=L11
                    SAV L15 VKIM292A4/A
L16                 STR
L17              13 S L16
L18             193 S L16 FUL
                    SAV L18 VKIM292C1/A
L19                 STR L16
L20              13 S L19 CSS SAM SUB=L18
L21             187 S L19 CSS FUL SUB=L18
                    SAV L21 VKIM292C2/A
L22                 STR L19
                    DEL VKIM292C2/A
L23               0 S L22 CSS SAM SUB=L18
L24               0 S L22 CSS FUL SUB=L18
                    SAV L24 VKIM292C2/A
                    SAV L21 VKIM292C3/A
L25                 STR L19
L26               1 S L25 CSS SAM SUB=L21
L27              18 S L25 CSS FUL SUB=L21
                    SAV L27 VKIM292C4/A
L28             169 S L21 NOT L27
L29              35 S L28 NOT SQL/FA
L30               7 S L29 AND (T/ELS OR 14C OR C29H41N5O4 OR C26H35N5O4 OR C27H37N5
L31              28 S L29 NOT L30
L32              46 S L27,L31
                    SAV L32 VKIM292C5/A

     FILE 'HCAPLUS' ENTERED AT 14:54:22 ON 11 MAR 2004
L33               1 S (US20030078273 OR US20020049206)/PN OR WO2001-US25603/AP,PRN
                    E ANDERSON R/AU
L34             273 S E3
                    E ANDERSON R W/AU
L35              54 S E3-E5
                    E ANDERSON RICK/AU
                    E ANDERSON RICH/AU
L36              59 S E4
                    E ANDERSON RICHARD 2/AU
                    E ANDERSON RICHARD W/AU
L37              29 S E3-E5
                    E MCBRINN S/AU
L38               2 S E5,E6
                    E MC BRINN S/AU
```

```
                E ROBERTSON D/AU
L39          92 S E3
                E ROBERTSON D W/AU
L40          48 S E3
L41         154 S E25,E26
                E ROBERTSON DAVID W/AU
L42         169 S E3-E5
                E MARSHALL R/AU
L43         243 S E3,E8
                E MARSHALL ROB/AU
L44         163 S E4,E8-E10
L45           1 S L33 AND L34-L44
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:33:34 ON 11 MAR 2004
L46          14 S E1-E14
L47           3 S L46 AND L11
L48           1 S L46 AND L32
L49           3 S L46 AND 46.150.18/RID AND (NC3 OR NC4 OR NC5 OR NC6)/ES
L50           7 S L46 NOT L47-L49
L51           6 S L50 NOT ETHANOL
L52           1 S L51 AND 2/NR
L53           5 S L51 NOT L52
L54           1 S ETHANOL/CN

     FILE 'HCAPLUS' ENTERED AT 15:44:05 ON 11 MAR 2004
L55           5 S L53
L56          20 S L47
L57         226 S L48
L58           8 S L49
L59         276 S CABERGOLIN# OR DOSTINEX OR GAGASTOP OR SOGILEN# OR CABASER#
L60         306 S L55-L59
L61         180 S L60 AND (PD<=20000816 OR PRD<=20000816 OR AD<=20000816)
L62           3 S L34-L44 AND L60
L63           3 S L45,L62
L64         189 S (L53 OR L47 OR L48 OR L49)(L)THU/RL
L65         100 S L61 AND L64
L66      182676 S L52 OR L54
L67           5 S L65 AND L66
L68           5 S L61 AND L66
L69           7 S L63,L67,L68
L70         287 S L11 OR L32
L71         188 S L70 AND (PD<=20000816 OR PRD<=20000816 OR AD<=20000816)
L72         199 S (L11 OR L32)(L)THU/RL
L73         109 S L71 AND L72
L74           5 S L73 AND L66
L75           7 S L69,L74
                E TOBACCO/CT
L76       31172 S E3+NT
                E E3+ALL
L77           1 S E8
                E SMOKE/CT
                E E3+ALL
L78       23964 S E15+NT
                E ADDICTION/CT
                E DRUG DEPENDENCE/CT
L79        8707 S E3,E4
                E E3+ALL
L80       13006 S E3+NT
L81        7231 S E8+NT
L82       42741 S E10+NT
                E E10+ALL
L83         362 S E2
```

```
L84          10 S L72 AND L76-L83
L85           2 S L75 AND L84
L86           8 S L84 NOT L85
L87           7 S L75,L85
L88         221 S L61,L71
L89          12 S L88 AND (NICOTINE OR TOBACCO OR CIGAR? OR SMOKE OR SMOKING OR
L90           9 S L89 NOT L87
L91           3 S L87 AND L89
L92           7 S L87,L91

     FILE 'REGISTRY' ENTERED AT 15:56:42 ON 11 MAR 2004

=> d ide can tot l53

L53  ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   400716-32-7  REGISTRY
CN   Benzenesulfonamide, N-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-
     piperazinyl]-, (-)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C21 H27 N3 O3 S
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

Rotation (-).
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  136:205395

L53  ANSWER 2 OF 5  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   400716-30-5  REGISTRY
CN   Benzamide, N-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]-
     , (-)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C22 H27 N3 O2
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

Rotation (-).
```



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:205395

L53 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN **400716-28-1** REGISTRY
CN Piperazine, 1-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H26 N2 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:205395

L53 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN **170858-41-0** REGISTRY
CN Piperazine, 1-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H28 N2 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:62616

REFERENCE 2: 136:205395

REFERENCE 3: 129:36411

REFERENCE 4: 125:48345

REFERENCE 5: 124:8845

L53 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN **170858-36-3** REGISTRY
CN Piperazine, 1-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H25 F N2 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:62616

REFERENCE 2: 136:205395

REFERENCE 3: 125:48345

REFERENCE 4: 124:8845

=> d ide can l47 tot

L47 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN **282522-94-5** REGISTRY
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H13 N3 S . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:169640

REFERENCE 2: 139:185666

REFERENCE 3: 139:185665

REFERENCE 4: 137:174924

REFERENCE 5: 136:355238

REFERENCE 6: 136:205395

REFERENCE 7: 135:344486

REFERENCE 8: 135:331428

REFERENCE 9: 133:109946

L47 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN **282522-93-4** REGISTRY
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (5R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione
FS STEREOSEARCH
MF C11 H13 N3 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

10 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:185666

REFERENCE 2: 139:185665

REFERENCE 3: 138:78475

REFERENCE 4: 138:78468

REFERENCE 5: 137:174924

REFERENCE 6: 136:355238

REFERENCE 7: 136:205395

REFERENCE 8: 135:344486

REFERENCE 9: 135:331428

REFERENCE 10: 133:109946

L47 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN **179386-43-7** REGISTRY
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (R)-
OTHER NAMES:
CN Sumanirole
FS STEREOSEARCH
DR 194919-10-3
MF C11 H13 N3 O
CI COM
SR CAS Client Services
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, IMSRESEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

17 REFERENCES IN FILE CA (1907 TO DATE)
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:169640

REFERENCE 2: 140:117387

REFERENCE 3: 139:345938

REFERENCE 4: 139:185666

REFERENCE 5: 139:185665

REFERENCE 6: 139:90451

REFERENCE 7: 138:395249

REFERENCE 8: 138:78475

REFERENCE 9: 136:355238

REFERENCE 10: 136:205395

=> d ide can l48

L48 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **81409-90-7** REGISTRY
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
OTHER NAMES:
CN Cabaser
CN Cabergoline
CN Dostinex
CN Galastop
CN Sogilen
FS STEREOSEARCH
MF C26 H37 N5 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

225 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
226 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:156358

REFERENCE 2: 140:151959

REFERENCE 3: 140:139594

REFERENCE 4: 140:133869

REFERENCE 5: 140:117406

REFERENCE 6: 140:117387

REFERENCE 7: 140:105350

REFERENCE 8: 140:70067

REFERENCE 9: 139:374518

REFERENCE 10: 139:345938

=> d ide can 149 tot

L49 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN **369595-93-7** REGISTRY
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrobromide, (3S)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H23 N O2 S . Br H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
CRN (146798-66-5)

Absolute stereochemistry. Rotation (-).




● HBr

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:355238

REFERENCE 2: 136:205395

REFERENCE 3: 135:331428

L49 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN **173590-06-2** REGISTRY
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (S)-, (E)-2-butenedioate (1:1)
FS STEREOSEARCH
MF C15 H23 N O2 S . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 146798-66-5
CMF C15 H23 N O2 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:355238

REFERENCE 2: 136:205395

REFERENCE 3: 135:331428

REFERENCE 4: 124:175838

L49 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN **156907-84-5** REGISTRY
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrochloride, (3S)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrochloride, (S)-
OTHER NAMES:
CN OSU 6162 hydrochloride
FS STEREOSEARCH
MF C15 H23 N O2 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
CRN (146798-66-5)

Absolute stereochemistry. Rotation (-).




● HCl

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:90451

REFERENCE 2: 138:305763

REFERENCE 3: 136:355238

REFERENCE 4: 136:205395

REFERENCE 5: 135:331428

REFERENCE 6: 122:132923

REFERENCE 7: 121:124598

=> d ide can l52

L52 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN **54-11-5** REGISTRY
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotine (8CI)
CN Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-
OTHER NAMES:
CN (-)-β-Pyridyl-α-N-methylpyrrolidine
CN (-)-3-(1-Methyl-2-pyrrolidyl)pyridine
CN (-)-Nicotine
CN (S)-(-)-Nicotine
CN (S)-3-(1-Methyl-2-pyrrolidinyl)pyridine
CN (S)-Nicotine
CN 3-[(2S)-1-Methyl-2-pyrrolidinyl]pyridine
CN Flux Maag
CN Habitrol
CN l-Nicotine
CN L-Nicotine
CN Nicabate
CN Nicoderm
CN Nicolan
CN Niconil
CN Nicopatch
CN Nicorette
CN Nicotell TTS
CN Nicotin
CN Nicotinell
CN Nicotrol
CN NSC 5065
CN Tabazur
CN XL All Insecticide
FS STEREOSEARCH
DR 13890-81-8, 13890-82-9, 6912-85-2, 551-13-3, 16760-37-5
MF C10 H14 N2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

16300 REFERENCES IN FILE CA (1907 TO DATE)
245 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16326 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:169624

REFERENCE 2: 140:169440

REFERENCE 3: 140:161946

REFERENCE 4: 140:161107

REFERENCE 5: 140:160613

REFERENCE 6: 140:159636

REFERENCE 7: 140:158961

REFERENCE 8: 140:158957

REFERENCE 9: 140:158956

REFERENCE 10: 140:158954

=> d ide can 154

L54 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 64-17-5 REGISTRY
CN **Ethanol (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethyl alcohol (6CI, 7CI, 8CI)
OTHER NAMES:
CN 100C.NPA
CN AHD 2000
CN Alcare Hand Degermer
CN Alcohol
CN Alcohol anhydrous
CN Algrain
CN Anhydrol
CN Anhydrol PM 4085
CN Desinfektol EL
CN Duplicating Fluid 100C.NPA
CN Esumiru WK 88
CN Ethicap
CN Ethyl hydrate
CN Ethyl hydroxide
CN Hinetoless
CN IMS 99
CN Jaysol
CN Jaysol S
CN Lux
CN Methylcarbinol
CN Molasses alcohol
CN NSC 85228
CN Potato alcohol
CN SDA 3A
CN SDA 40-2
CN Sekundasprit
CN SY Fresh M
CN Synasol
CN Tecsol
CN Tecsol C
FS 3D CONCORD
DR 8000-16-6, 8024-45-1, 121182-78-3
MF C2 H6 O

CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

$H_3C-CH_2-OH$

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

166499 REFERENCES IN FILE CA (1907 TO DATE)
1188 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
166814 REFERENCES IN FILE CAPLUS (1907 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:174090

REFERENCE 2: 140:174049

REFERENCE 3: 140:173935

REFERENCE 4: 140:173761

REFERENCE 5: 140:173266

REFERENCE 6: 140:173060

REFERENCE 7: 140:172024

REFERENCE 8: 140:172016

REFERENCE 9: 140:172013

REFERENCE 10: 140:171897

=> => fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:58:29 ON 11 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Mar 2004 VOL 140 ISS 11
FILE LAST UPDATED: 10 Mar 2004 (20040310/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l92 all hitstr tot

L92 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:59549 HCAPLUS
DN 140:117387
ED Entered STN: 23 Jan 2004
TI Transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid
IN Klose, Kathryn Traci-jane; Tran, Ngan Thi Kim; Morgon, Timothy Matthias; Finnin, Barrie Charles; Reed, Barry Leonard
PA Monash University, Australia
SO U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 910,780.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K007-42
ICS A61K009-70
NCL 424059000; 424449000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2004013620 | A1 | 20040122 | US 2003-428016 | 20030502 <-- |
| | WO 9729735 | A1 | 19970821 | WO 1997-AU91 | 19970219 <-- |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6299900 | B1 | 20011009 | US 1998-125436 | 19981218 <-- |
| | AU 9952589 | A1 | 19991202 | AU 1999-52589 | 19991001 <-- |
| | US 2002028235 | A1 | 20020307 | US 2001-910780 | 20010724 <-- |
| PRAI | AU 1996-8411 | A | 19960219 <-- | | |
| | WO 1997-AU91 | W | 19970219 <-- | | |
| | US 1998-125436 | A3 | 19981218 <-- | | |
| | US 2001-910780 | A2 | 20010724 | | |
| | AU 1996-8144 | A | 19960219 <-- | | |
| | AU 1997-17134 | A3 | 19970219 <-- | | |

OS MARPAT 140:117387
AB The present invention provides a transder[illegible] which comprises: a therapeutically effective am[illegible] agent; at least one dermal penetration enhancer, wh[illegible]ant ester sunscreen ester; and at least one volatil[illegible] also provides a method for administering at le[illegible] systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention. The addition of the sunscreen ester dermal penetration enhancer, octyl salicylate, surprisingly caused a marked increase (>15-fold) in the transdermal delivery of ropinirole across the skin ($p<0.05$). A topical spray contains 5 % volume/volume ropinirole, 5 % volume/volume octyl salicylate, and aqueous ethanol.
ST transdermal delivery antiparkinson agent skin penetration enhancer;

false hit

ropinirole transdermal delivery octyl salicylate ethanol

IT Drug delivery systems
(lotions, topical; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT Sunscreens
(skin-tolerant ester; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT Drug delivery systems
(sprays, topical; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT Animal
Antiparkinsonian agents
Permeation enhancers
Skin
Thickening agents
Volatile substances
(transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT Drug delivery systems
(transdermal; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT 9003-01-4D, crosslinked
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Carbopol; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT 59-92-7, Levodopa, biological studies 77-37-2, Procyclidine 83-98-7, Orphenadrine 86-13-5, Benztropine 144-11-6 322-35-0, Benserazide 514-65-8, Biperiden 522-00-9, Ethopropazine 768-94-5, Amantadine 1744-22-5, Riluzole 3605-01-4, Piribedil 14611-51-9, Selegiline 16378-21-5, Piroheptine 19875-60-6, Lisuride hydrogen maleate 19982-08-2, Memantine 20448-86-6, Bornaprine 23651-95-8, Droxidopa 25614-03-3, Bromocriptine 28860-95-9, Carbidopa 37686-84-3, Terguride 57982-78-2, Budipine 66104-22-1, Pergolide 68693-11-8, Modafinil **81409-90-7**, **Cabergoline** 87056-78-8, Quinagolide 91374-21-9, Ropinirole 99755-59-6, Rotigotine 101626-70-4, Talipexole 103878-84-8, Lazabemide 104632-26-0, Pramipexole 130929-57-6, Entacapone 133865-89-1, Safinamide 134308-13-7, Tolcapone 161735-79-1, Rasagiline mesylate 161832-65-1, Talampanel 171655-91-7, Brasofensine 179120-92-4, Altinicline **179386-43-7**, Sumanirole 350992-10-8, Bifeprunox 500604-72-8, Spheramine
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antiParkinson agent; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT 118-60-5, Octyl salicylate
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(skin penetration enhancer; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT 1310-73-2, Sodium hydroxide, biological studies 7732-18-5, Water, biological studies 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 21245-02-3, Padimate O
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT **64-17-5**, Ethanol, biological studies 67-63-0, Isopropanol, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(volatile liquid; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)

IT **81409-90-7, Cabergoline 179386-43-7,** Sumanirole
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antiParkinson agent; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)
RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179386-43-7 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT **64-17-5**, Ethanol, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(volatile liquid; transdermal delivery of antiparkinson agents with skin penetration enhancer and volatile liquid)
RN 64-17-5 HCAPLUS
CN Ethanol (9CI) (CA INDEX NAME)




L92 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:319255 HCAPLUS
DN 138:343854
ED Entered STN: 25 Apr 2003

TI Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
IN Dugger, Harry A.
PA USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K009-00
ICS A61L009-04
NCL 424043000
CC 63-6 (Pharmaceuticals)
FAN.CNT 10

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 2003077227 | A1 | 20030424 | US 2002-230060 | 20020829 <-- |
| WO 9916417 | A1 | 19990408 | WO 1997-US17899 | 19971001 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| EP 1029536 | A1 | 20000823 | EP 2000-109347 | 19971001 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| EP 1036561 | A1 | 20000920 | EP 2000-109357 | 19971001 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |

PRAI WO 1997-US17899 A2 19971001 <--
US 2000-537118 A2 20000329 <--
EP 1997-911621 A3 19971001 <--

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

ST buccal spray central nervous system disease; capsule central nervous system disease
IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C2-26; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C2-8; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C7-18; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C7-18; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Prostaglandins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Antihistamines
(H2; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Drug delivery systems
(aerosols; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Benzodiazepine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Mental disorder
(attention deficit disorder; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Adrenoceptor antagonists
Alzheimer's disease
Antibiotics
Anticonvulsants
Antidepressants
Antiparkinsonian agents
Antipsychotics
Antiviral agents
Anxiolytics
Cholinergic antagonists
Flavoring materials
Fungicides
Hypnotics and Sedatives
Molecular weight distribution
Neurotransmitter agonists
Neurotransmitter antagonists
Polar solvents
Propellants (sprays and foams)
Sweetening agents
Tranquilizers
(buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Esters, biological studies
Hormones, animal, biological studies
Neurotransmitters
Peptides, biological studies
Polyoxyalkylenes, biological studies
Prostaglandins
Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Drug delivery systems
(buccal; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Drug delivery systems
(capsules; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Nervous system, disease
(central; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citrus; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT Fatty acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters, C2-24; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Echinacea
Valerian (Valeriana)
(exts.; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Flavoring materials
(fruit flavors; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Mouth
(mucosa; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Sleep
(narcolepsy; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Cytoprotective agents
(neuroprotective; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyhydric, C2-8; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spearmint; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Drug delivery systems
(sprays; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Brain, disease
(stroke; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Diet
(supplements; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β, 1A; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β, 1B; buccal sprays or capsule containing drugs for treating disorders of central nervous system)

IT 50-06-6, Phenobarbital, biological studies 50-28-2, Estradiol, biological studies 50-47-5, Desipramine 50-48-6 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-67-9, Serotonin, biological studies 51-30-9, Isoproterenol Hydrochloride 51-41-2, Norepinephrine 51-43-4, Epinephrine 51-45-6, Histamine, biological studies 51-61-6, Dopamine, biological studies 51-64-9, Dextroamphetamine 51-71-8, Phenelzine 51-84-3, Acetylcholine, biological studies 52-86-8, Haloperidol 56-12-2, GABA, biological studies 56-40-6, Glycine, biological studies 56-65-5, ATP, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies 57-41-0, Phenytoin 57-47-6, Physostigmine 57-83-0, Progesterone, biological studies 57-94-3, Tubocurarine 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-92-7, Levodopa, biological studies 59-99-4, Neostigmine 60-87-7,

Promethazine **64-17-5**, Ethanol, biological studies 67-52-7D, 2,4,6(1H,3H,5H)-Pyrimidinetrione, derivs. 68-88-2, Hydroxyzine 72-69-5 74-98-6, Propane, biological studies 75-28-5, Isobutane 77-19-0, Dicycloverine 77-67-8, Ethosuximide 78-78-4, Isopentane 95-25-0, Chlorzoxazone 96-88-8, Mepivacaine 106-97-8, N-Butane, biological studies 109-66-0, N-Pentane, biological studies 113-45-1, Methylphenidate 114-07-8, Erythromycin 125-33-7, Primidone 127-48-0, Trimethadione 137-58-6, Lidocaine 147-24-0, Diphenhydramine hydrochloride 155-09-9, Tranylcypromine 298-46-4, Carbamazepine 300-62-9, Amphetamine 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 312-48-1, Edrophonium 321-64-2, Tacrine 322-35-0, Benserazide 357-70-0, Galantamine 363-24-6, Dinoprostone 438-60-8, Protriptyline 439-14-5, Diazepam 463-82-1, Neopentane 511-12-6, Dihydroergotamine 523-87-5, Dimenhydrinate 569-65-3, Meclizine 721-50-6, Prilocaine 768-94-5, Amantadine 1622-61-3, Clonazepam 1668-19-5, Doxepin 1744-22-5, Riluzole 2078-54-8, Propofol 2152-34-3, Pemoline 3239-45-0, Dexfenfluramine hydrochloride 3313-26-6, Thiothixene 5588-33-0, Mesoridazine 5786-21-0, Clozapine 10102-43-9, Nitric oxide, biological studies 10238-21-8, Glyburide 10262-69-8, Maprotiline 10457-90-6, Bromperidol 14028-44-5, Amoxapine 14611-51-9, Selegiline 15500-66-0, Pancuronium 15676-16-1, Sulpiride 17780-72-2, Clorgyline 19794-93-5, Trazodone 19982-08-2, Memantine 22232-71-9, Mazindol 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23887-31-2, Clorazepate 25322-68-3, Polyethylene glycol 25614-03-3, Bromocriptine 27262-47-1, Levobupivacaine 27848-84-6, Nicergoline 28721-07-5, Oxcarbazepine 28860-95-9, Carbidopa 30516-87-1, Zidovudine 34911-55-2, Bupropion 36505-84-7, Buspirone 43200-80-2, Zopiclone 47931-85-1, Salmon Calcitonin 50700-72-6, Vecuronium 51022-70-9, Albuterol sulfate 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 59729-33-8, Citalopram 60142-96-3, Gabapentin 60205-81-4, Ipratropium 61869-08-7, Paroxetine 63798-73-2, Cyclosporine 64228-79-1, Atracurium 64840-90-0, Eperisone 66085-59-4, Nimodipine 66104-22-1, Pergolide 68291-97-4, Zonisamide 68399-58-6, Pipecuronium 68506-86-5, Vigabatrin 68693-11-8, Modafinil 70059-30-2, Cimetidine hydrochloride 71320-77-9, Moclobemide 71675-85-9, Amisulpride 72432-10-1, Aniracetam 76584-70-8 76824-35-6, Famotidine 77191-36-7, Nefiracetam 77337-76-9, Acamprosate 78755-81-4, Flumazenil 79517-01-4, Sandostatin 79617-96-2, Sertraline **81409-90-7**, **Cabergoline** 82626-48-0, Zolpidem 83015-26-3, Atomoxetine 83366-66-9, Nefazodone 84057-84-1, Lamotrigine 84057-95-4, Ropivacaine 85650-52-8, Mirtazapine 90293-01-9, Bifemelane 91374-21-9, Ropinirole 93107-08-5, Ciprofloxacin hydrochloride 93413-69-5, Venlafaxine 96946-41-7, Cisatracurium 97240-79-4, Topiramate 99571-64-9, Oxitropium 99614-01-4, Ondansetron hydrochloride 102767-28-2, Levetiracetam 103628-46-2, Sumatriptan 103628-48-4, Sumatriptan succinate 103878-84-8, Lazabemide 104632-26-0, Pramipexole 106266-06-2, Risperidone 106650-56-0, Sibutramine 106861-44-3, Mivacurium chloride 111974-69-7, Quetiapine 113775-47-6, Dexmedetomidine 115103-54-3, Tiagabine 116539-59-4, Duloxetine 120014-06-4, Donepezil 120444-71-5, Deramciclane 121679-13-8, Naratriptan 123441-03-2, Rivastigmine 128196-01-0, Escitalopram 128298-28-2, Remacemide 129722-12-9, Aripiprazole 130929-57-6, Entacapone 132539-06-1, Olanzapine 133107-64-9, Insulin lispro 133454-47-4, Iloperidone 133737-32-3, Pagoclone 133814-18-3, Doxacurium 134308-13-7, Tolcapone 135354-02-8, Xaliproden 138729-47-2, Esopiclone 139264-17-8, Zolmitriptan 142852-51-5, TAK147 143322-58-1, Eletriptan 143558-00-3, Rocuronium 144034-80-0, Rizatriptan 146939-27-7, Ziprasidone 148553-50-8, Pregabalin 151319-34-5, Zaleplon 154323-57-6, Almotriptan 156137-99-4, Rapacuronium bromide 214415-55-1 325715-02-4, Indiplon 515132-12-4 516482-86-3, Sermorelin acetate

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(buccal sprays or capsule containing drugs for treating disorders of

central nervous system)
IT 9000-81-1, Acetylcholinesterase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; buccal sprays or capsule containing drugs for treating disorders of central nervous system)
IT **64-17-5**, Ethanol, biological studies **81409-90-7**, **Cabergoline**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(buccal sprays or capsule containing drugs for treating disorders of central nervous system)
RN 64-17-5 HCAPLUS
CN Ethanol (9CI) (CA INDEX NAME)

$H_3C-CH_2-OH$

RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L92 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:353281 HCAPLUS
DN 136:355238
ED Entered STN: 12 May 2002
TI Preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome
IN **McBrinn, Sylvia; Anderson, Richard W.**
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-445
ICS A61K031-48; A61P019-00
CC 28-9 (Heterocyclic Compounds (More Than One H
Section cross-reference(s): 1, 63

applicants

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002036123 | A2 | 20020510 | WO 2001-US27785 | 20011029 |
| | WO 2002036123 | A3 | 20020919 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU | 2002011226 | A5 | 20020515 | AU 2002-11226 | 20011029 |
| US | 2002107257 | A1 | 20020808 | US 2001-39446 | 20011029 |
| US | 6602868 | B2 | 20030805 | | |
| BR | 2001015071 | A | 20030729 | BR 2001-15071 | 20011029 |
| EP | 1330248 | A2 | 20030730 | EP 2001-979241 | 20011029 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US | 2003212065 | A1 | 20031113 | US 2003-423078 | 20030425 |
| NO | 2003001923 | A | 20030627 | NO 2003-1923 | 20030429 |
| PRAI US | 2000-244666P | P | 20001031 | | |
| US | 2001-39446 | A3 | 20011029 | | |
| WO | 2001-US27785 | W | 20011029 | | |

OS MARPAT 136:355238

GI




I




II




III




IV

AB Invention compds. I and II [R1-3 = H, alk(en/yn)yl, cycloalkyl, cycloalkyl or R1-2 are joined to form a cyclic amine; X = H, alkyl, halo, hydroxy, alkoxy, cyano, carboxamide, carboxy, carboalkoxyl; A = CH, CH2, CH-halo, CHCH3, C=O, C=S, C-SCH3, C=NH, C-NH2, C-NHCH3, C-NHCOOCH3, C-NHCN, SO2, N; B = CH2, CH, CH-halo, C=O, N, NH, N-CH3; n = 0-1; D = CH, CH2, CH-halo, C=O, O, N, NH, N-CH3; p = 0-3; R4-5 = H (provided only one is H at the same time), OH (provided R7 is other than hydrogen), CN, CH2CN, 2- or 4-CF3, CH2CF3, CH2CHF2, CH=CF2, (CH2)2CF3, ethenyl, 2-propenyl, OSO2CH3,

OSO2CF3, SSO2CF3, COR7, COOR7, CON(R7)2, SO0-2CH3, SO0-2CF3, etc.; R6 = H, CF3, CH2CF3, alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, etc.; R7 = H, CF3, CH2CF3, alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl,etc.] were prepared For instance, (R)-Naproxen chloride (preparation given) was coupled to 1-Benzyl-5-bromo-6-hydroxy-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (preparation given) and the resulting ester treated with MeNH2 in CH3CN to afford intermediate amino alc. III. III was converted to the aziridine via the benzenesulfonate and subsequently treated with Li/NH3 to effect debenzylation and aziridine ring opening. The resulting amide was converted to thioamide IV (pyridine, P4S10, 125°C, 5 h). I and II are useful for treating restless leg syndrome (RLS).

ST treatment restless leg syndrome imidazoquinoline quinoline imidazole prepn piperidine

IT Human
(preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome)

IT 146798-66-5P **156907-84-5P 173590-06-2P 179386-43-7P** 179386-44-8P **282522-93-4P 282522-94-5P 369595-93-7P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome)

IT 105927-04-6P 227025-33-4P 269731-84-2P 282522-95-6P 282522-96-7P 282522-98-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome)

IT 23979-41-1 83848-83-3, 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome)

IT **156907-84-5P 173590-06-2P 179386-43-7P 282522-93-4P 282522-94-5P 369595-93-7P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome)

RN 156907-84-5 HCAPLUS

CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 173590-06-2 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146798-66-5
CMF C15 H23 N O2 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 179386-43-7 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 282522-93-4 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 369595-93-7 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HBr

L92 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:142501 HCAPLUS
DN 136:205395
ED Entered STN: 22 Feb 2002
TI Compounds for the treatment of addictive disorders
IN **Anderson, Richard W.; McBrinn, Sylvia S.;**

**Robertson, David W.; Marshall, Robert C.**
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002013807 | A2 | 20020221 | WO 2001-US25603 | 20010813 <-- |
| WO 2002013807 | A3 | 20030925 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001083393 | A5 | 20020225 | AU 2001-83393 | 20010813 <-- |
| EP 1363634 | A2 | 20031126 | EP 2001-962196 | 20010813 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004506621 | T2 | 20040304 | JP 2002-518953 | 20010813 <-- |
| US 2002049206 | A1 | 20020425 | US 2001-929666 | 20010814 <-- |
| US 2003078273 | A1 | 20030424 | US 2002-295331 | 20021115 <-- |
| NO 2003000717 | A | 20030214 | NO 2003-717 | 20030214 <-- |
| PRAI US 2000-225714P | P | 20000816 <-- | | |
| US 2001-263610P | P | 20010123 | | |
| WO 2001-US25603 | W | 20010813 <-- | | |
| US 2001-929666 | A3 | 20010814 | | |

OS MARPAT 136:205395
GI




I

applicants




II

AB The treatment of **addictive** disorders, psychoactive **substance** use disorders, intoxication disorders, inhalation

disorders, **alc. addiction, tobacco addiction**, and **nicotine addiction** using a heterocyclic amine, a phenylazacycloalkane, a **cabergoline**, or an aromatic bicyclic amine active agent, or a pharmaceutically acceptable derivative or salt of any said active agent is described. Example compds. are I and II.

ST addiction disorder treatment; heterocyclic amine addiction disorder treatment; phenyl azacycloalkane addiction disorder treatment; **cabergoline** addiction disorder treatment

IT **Drug dependence**
**Tobacco smoke**
(compds. for the treatment of **addictive** disorders)

IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic; compds. for the treatment of addictive disorders)

IT **54-11-5, Nicotine 64-17-5, Ethanol,** biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compds. for the treatment of **addictive** disorders)

IT **81409-90-7, Cabergoline 156907-84-5 170858-36-3 170858-41-0 173590-06-2 179386-43-7 282522-93-4 282522-94-5 369595-93-7 400716-28-1 400716-30-5 400716-32-7**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compds. for the treatment of addictive disorders)

IT **54-11-5, Nicotine 64-17-5, Ethanol,** biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compds. for the treatment of **addictive** disorders)

RN 54-11-5 HCAPLUS
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 64-17-5 HCAPLUS
CN Ethanol (9CI) (CA INDEX NAME)

$H_3C—CH_2—OH$

IT **81409-90-7, Cabergoline 156907-84-5 170858-36-3 170858-41-0 173590-06-2 179386-43-7 282522-93-4 282522-94-5 369595-93-7 400716-28-1 400716-30-5 400716-32-7**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compds. for the treatment of addictive disorders)

RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156907-84-5 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 170858-36-3 HCAPLUS
CN Piperazine, 1-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 170858-41-0 HCAPLUS
CN Piperazine, 1-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 173590-06-2 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146798-66-5
CMF C15 H23 N O2 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 179386-43-7 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 282522-93-4 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 369595-93-7 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrobromide, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HBr

RN 400716-28-1 HCAPLUS
CN Piperazine, 1-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 400716-30-5 HCAPLUS
CN Benzamide, N-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 400716-32-7 HCAPLUS
CN Benzenesulfonamide, N-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



L92 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:798221 HCAPLUS
DN 135:331428
ED Entered STN: 02 Nov 2001
TI Preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome.
IN McCall, Robert B.; **Marshall, Robert C.**; **Robertson, David W.**; Ashley, Thomas M.
PA Pharmacia + Upjohn Company, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D471-00
CC 28-9 (Heterocyclic Compounds (More Than
Section cross-reference(s): 1, 27

applicants

FAN.CNT 1

| | PATENT NO. | KIND | DATE | AP |
|---|---|---|---|---|
| PI | WO 2001081343 | A2 | 20011101 | WO |
| | WO 2001081343 | A3 | 20020228 | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, [illegible] CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2002004510 | A1 | 20020110 | US 2001-836660 20010417 |
| | US 6448258 | B2 | 20020910 | |
| | EP 1274430 | A2 | 20030115 | EP 2001-926590 20010417 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | BR 2001010210 | A | 20030128 | BR 2001-10210 20010417 |
| | JP 2004502650 | T2 | 20040129 | JP 2001-578433 20010417 |
| | US 2002143010 | A1 | 20021003 | US 2002-159913 20020530 |
| | US 6555548 | B2 | 20030429 | |
| | US 2003191149 | A1 | 20031009 | US 2003-383467 20030307 |
| PRAI | US 2000-198959P | P | 20000421 | |

| | | | |
|---|---|---|---|
| | US 2000-200569P | P | 20000428 |
| | US 2001-836660 | A3 | 20010417 |
| | WO 2001-US10807 | W | 20010417 |
| | US 2002-159913 | A3 | 20020530 |

OS MARPAT 135:331428

GI




I

AB Use of title compds., e.g., (I; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, phenylalkyl; R1R2N = cyclic amine; X = H, alkyl, halo, OH, alkoxy, cyano, carboxamide, CO2H, carboalkoxy; A = CH, CH2, CHY, CHMe, CO, CS, CSMe, CNH2, SO2, N, etc.; B = null, CH2, CH, CHY, CO, N, NH, NMe, O; D = CH, CH2, CHY, CO, O, N, NH, NMe; Y = halo) for preparation of medicaments for the treatment of symptoms of fibromyalgia or chronic fatigue syndrome is claimed (no data). Thus, 4H-imidazo[4,5,1-ij]quinolin-2(1H)-one was converted in several steps to (5R)-5-methylamino-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione in several steps.

ST heterocyclic amine prepn fibromyalgia chronic fatigue syndrome treatment; imidazoquinolinone prepn fibromyalgia chronic fatigue syndrome treatment; methylsulfonylphenylpropylpiperidine prepn fibromyalgia chronic fatigue syndrome treatment; **cabergoline** fibromyalgia chronic fatigue syndrome treatment

IT Fatigue, biological
(chronic fatigue syndrome, treatment; preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT Muscle, disease
(fibromyalgia, treatment; preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT Amines, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic; preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT **282522-93-4P**, (5R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione **282522-94-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT **81409-90-7**, **Cabergoline 156907-84-5**
**173590-06-2 179386-43-7** 179386-44-8
**369595-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT 282522-97-8P

RL: BYP (Byproduct); PREP (Preparation)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT 269731-84-2P, (5R,6R)-1-Benzyl-5-hydroxy-6-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-one
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT 74-89-5, Methylamine, reactions 83848-83-3, 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT 227025-33-4P, 1-Benzyl-4H-imidazo[4,5,1-ij]quinoline-2(1H)-one 282522-96-7P 369595-91-5P, (5R,6R)-1-Benzyl-5-bromo-6-hydroxy-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-one 369595-92-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

IT **282522-93-4P**, (5R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione **282522-94-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

RN 282522-93-4 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282522-94-5 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




IT **81409-90-7, Cabergoline 156907-84-5**
**173590-06-2 179386-43-7 369595-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)
RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156907-84-5 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, hydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 173590-06-2 HCAPLUS
CN Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146798-66-5
CMF C15 H23 N O2 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 179386-43-7 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L92 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:553395 HCAPLUS
DN 133:155456
ED Entered STN: 11 Aug 2000
TI Topical sprays containing film-forming polymers
IN Lulla, Amar; Malhotra, Geena; Raut, Preeti
PA Cipla Limited, India
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
IC A61K009-70; A61K009-12
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|---|
| PI | WO 2000045795 | A2 | 20000810 | WO 2000-GB366 | 20000207 | <-- |
| | WO 2000045795 | A3 | 20010809 | | | |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | IN 186668 | A | 20011020 | IN 1999-BO93 | 19990205 | <-- |
| | CA 2359640 | AA | 20000810 | CA 2000-2359640 | 20000207 | <-- |
| | AU 2000024472 | A5 | 20000825 | AU 2000-24472 | 20000207 | <-- |
| | AU 759515 | B2 | 20030417 | | | |
| | BR 2000007997 | A | 20011030 | BR 2000-7997 | 20000207 | <-- |
| | EP 1150661 | A2 | 20011107 | EP 2000-902727 | 20000207 | <-- |
| | EP 1150661 | B1 | 20031022 | | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | | |
| | JP 2002536319 | T2 | 20021029 | JP 2000-596915 | 20000207 | <-- |
| | NZ 513208 | A | 20030530 | NZ 2000-513208 | 20000207 | <-- |
| | AT 252380 | E | 20031115 | AT 2000-902727 | 20000207 | <-- |
| | ZA 2000005727 | A | 20001221 | ZA [illegible] | [illegible] | <-- |
| | NO 2001003815 | A | 20011002 | NO [illegible] | [illegible] | <-- |
| PRAI | IN 1999-BO92 | A | 19990205 | <-- | | |
| | IN 1999-BO93 | A | 19990205 | <-- | | |
| | IN 1999-BO382 | A | 19990520 | <-- | | |
| | IN 1999-BO582 | A | 19990817 | <-- | | |
| | WO 1999-GB2998 | W | 19990909 | <-- | | |
| | IN 2000-BO43 | A | 20000113 | <-- | | |
| | IN 2000-BO44 | A | 20000113 | <-- | | |
| | WO 2000-GB366 | W | 20000207 | <-- | | |

False hit

AB A topical, medicinal spray composition c[illegible] [illegible] more medicaments in a volatile vehicle, and one or more film-forming polymers. When sprayed on a topical site, the composition forms a stable, breathable film from which the medicaments are transdermally available. Preferably, the composition comprises 0.1-30 % of one or more medicaments, 0.1-15 % film-forming polymers, 0.1-10 % solubilizers, 0.1-8 % permeation enhancers, 1.0-10 % plasticizers, and a vehicle q.s. 100 %. The invention includes a spray dispenser containing the topical composition An aerosol contained estradiol 2, PVP
K-30 6, vinylacetate-vinylpyrrolidone copolymer 4, vitamin E 1, polyethylene glycol-6000 2, polyethylene glycol 3, dichlorodifluoromethane 24.9, and trichloromonofluoromethane 57.1 %.

ST topical aerosol spray film forming polymer; estradiol vinyl polymer aerosol spray

IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10, ethoxylated, solubilizer; topical sprays containing film-forming polymers)

IT Drug delivery systems
(aerosols; topical sprays containing film-forming polymers)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; topical sprays containing film-forming polymers)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; topical sprays containing film-forming polymers)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plasticizer; topical sprays containing film-forming polymers)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric, solubilizer; topical sprays containing film-forming polymers)

IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solubilizer; topical sprays containing film-forming polymers)

IT Drug delivery systems
(sprays; topical sprays containing film-forming polymers)

IT 124-38-9, Carbon dioxide, biological studies 7727-37-9, Nitrogen, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compressed gas, propellant; topical sprays containing film-forming polymers)

IT 67-68-5, Dimethylsulfoxide, biological studies 68-12-2, Dimethyl formamide, biological studies 89-78-1, Menthol 110-27-0, Isopropyl myristate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 9005-65-6, Tween 80 21245-02-3, Padimate O
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(permeation enhancer; topical sprays containing film-forming polymers)

IT 77-90-7, Acetyl tributyl citrate 77-93-0, Triethyl citrate 5306-85-4, Dimethylisosorbide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plasticizer; topical sprays containing film-forming polymers)

IT 75-45-6, Monochlorodifluoromethane 75-71-8, Dichlorodifluoromethane 1320-37-2, Dichlorotetrafluoroethane 25167-88-8, Dichlorofluoroethane 25497-28-3, Difluoroethane 29759-38-4, Tetrafluoroethane 33660-75-2, Heptafluoropropane
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(propellant; topical sprays containing film-forming polymers)

IT 57-55-6, Propylene glycol, biological studies 108-32-7, Propylene carbonate 151-21-3, Sodium lauryl sulfate, biological studies 1406-18-4, Vitamin E 9002-96-4, TPGS 25322-68-3, Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solubilizer; topical sprays containing film-forming polymers)

IT 67-63-0, Isopropanol, biological studies 67-64-1, Acetone, biological studies 75-09-2, Methylene chloride, biological studies 75-69-4, Trichloromonofluoromethane 78-93-3, Methyl ethyl ketone, biological studies 109-87-5, Methylene dimethyl ether 141-78-6, Ethyl acetate, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solvent; topical sprays containing film-forming polymers)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-28-2, Estradiol, biological studies 50-47-5, Desipramine 50-49-7, Imipramine 51-34-3, Scopolamine 51-55-8, Atropine, biological studies 52-53-9, Verapamil 53-86-1, Indomethacin **54-11-5**, **Nicotine** 55-63-0,

Nitroglycerin 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 67-73-2, Fluocinolone acetonide 68-22-4, Norethisterone 73-31-4, Melatonin 77-86-1, Tromethamine 87-33-2, Isosorbide dinitrate 101-31-5, Hyoscyamine 144-11-6, Trihexyphenidyl 318-98-9, Propranolol hydrochloride 378-44-9, Betamethasone 439-14-5, Diazepam 537-46-2, Methamphetamine 745-65-3, Alprostadil 846-49-1, Lorazepam 1622-61-3, Clonazepam 2609-46-3, Amiloride 2809-21-4, Etidronic acid 4205-90-7, Clonidine 5534-09-8, Beclomethasone dipropionate 5633-20-5, Oxybutynin 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8, Povidone 9004-10-8, Insulin, biological studies 9004-35-7, Cellulose acetate 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 10238-21-8, Glyburide 11000-17-2, Vasopressin 14611-51-9, Selegiline 15307-79-6, Diclofenac sodium 15687-27-1, Ibuprofen 15826-37-6, Sodium cromoglycate 18559-94-9, Salbutamol 19216-56-9, Prazosin 22071-15-4, Ketoprofen 24938-16-7, Eudragit E100 25086-89-9, Vinylacetate-vinylpyrrolidone copolymer 25608-33-7, Butyl methacrylate-methyl methacrylate copolymer 25614-03-3, Bromocriptine 26159-34-2, Naproxen sodium 26921-17-5, Timolol maleate 29094-61-9, Glipizide 36322-90-4, Piroxicam 40391-99-9, Pamidronic acid 51333-22-3, Budesonide 51803-78-2, Nimesulide 53179-11-6, Loperamide 54910-89-3, Fluoxetine 59122-46-2, Misoprostol 61869-08-7, Paroxetine 62571-86-2, Captopril 63590-64-7, Terazosin 66376-36-1, Alendronic acid 72509-76-3, Felodipine 74103-06-3, Ketorolac 74191-85-8, Doxazosin 74381-53-6, Leuprolide acetate 76547-98-3, Lisinopril 76932-56-4, Nafarelin 80474-14-2, Fluticasone propionate **81409-90-7**, **Cabergoline** 81732-65-2, Bambuterol 83919-23-7, Mometasone furoate 84485-00-7, Sibutramine hydrochloride 87679-37-6, Trandolapril 88150-42-9, Amlodipine 89699-18-3, Isoprenaline sulfate 93479-97-1, Glimepiride 94749-08-3, Salmeterol xinafoate 98319-26-7, Finasteride 103628-46-2, Sumatriptan 106133-20-4, Tamsulosin 115103-54-3, Tiagabine 121679-13-8, Naratriptan 122320-73-4, Rosiglitazone 129318-43-0, Alendronate sodium 139264-17-8, Zolmitriptan 139755-83-2, Sildenafil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(topical sprays containing film-forming polymers)

IT **54-11-5**, **Nicotine 81409-90-7**, **Cabergoline**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(topical sprays containing film-forming polymers)

RN 54-11-5 HCAPLUS
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




=> => d his

(FILE 'HOME' ENTERED AT 13:49:45 ON 11 MAR 2004)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 13:50:08 ON 11 MAR 2004

```
L1              STR
L2           13 S L1
L3          269 S L1 FUL
                SAV L3 VKIM929A/A
L4              STR L1
L5           10 S L4 CSS SAM SUB=L3
L6          204 S L4 CSS FUL SUB=L3
                SAV L6 VKIM929A1/A
L7              STR L4
L8           32 S L7 CSS FUL SUB=L6
                SAV L8 VKIM929A2/A
L9              STR L7
L10         171 S L9 CSS FUL SUB=L6
                SAV L10 VKIM929A3/A
L11         203 S L8,L10
L12          66 S L3 NOT L11
L13             STR L1
L14          10 S L13 CSS SAM SUB=L11
L15         191 S L13 CSS FUL SUB=L11
                SAV L15 VKIM292A4/A
L16             STR
L17          13 S L16
L18         193 S L16 FUL
                SAV L18 VKIM292C1/A
L19             STR L16
L20          13 S L19 CSS SAM SUB=L18
L21         187 S L19 CSS FUL SUB=L18
                SAV L21 VKIM292C2/A
L22             STR L19
                DEL VKIM292C2/A
L23           0 S L22 CSS SAM SUB=L18
L24           0 S L22 CSS FUL SUB=L18
                SAV L24 VKIM292C2/A
                SAV L21 VKIM292C3/A
L25             STR L19
L26           1 S L25 CSS SAM SUB=L21
```

```
L27          18 S L25 CSS FUL SUB=L21
                SAV L27 VKIM292C4/A
L28         169 S L21 NOT L27
L29          35 S L28 NOT SQL/FA
L30           7 S L29 AND (T/ELS OR 14C OR C29H41N5O4 OR C26H35N5O4 OR C27H37N5
L31          28 S L29 NOT L30
L32          46 S L27,L31
                SAV L32 VKIM292C5/A

     FILE 'HCAPLUS' ENTERED AT 14:54:22 ON 11 MAR 2004
L33           1 S (US20030078273 OR US20020049206)/PN OR WO2001-US25603/AP,PRN
                E ANDERSON R/AU
L34         273 S E3
                E ANDERSON R W/AU
L35          54 S E3-E5
                E ANDERSON RICK/AU
                E ANDERSON RICH/AU
L36          59 S E4
                E ANDERSON RICHARD 2/AU
                E ANDERSON RICHARD W/AU
L37          29 S E3-E5
                E MCBRINN S/AU
L38           2 S E5,E6
                E MC BRINN S/AU
                E ROBERTSON D/AU
L39          92 S E3
                E ROBERTSON D W/AU
L40          48 S E3
L41         154 S E25,E26
                E ROBERTSON DAVID W/AU
L42         169 S E3-E5
                E MARSHALL R/AU
L43         243 S E3,E8
                E MARSHALL ROB/AU
L44         163 S E4,E8-E10
L45           1 S L33 AND L34-L44
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:33:34 ON 11 MAR 2004
L46          14 S E1-E14
L47           3 S L46 AND L11
L48           1 S L46 AND L32
L49           3 S L46 AND 46.150.18/RID AND (NC3 OR NC4 OR NC5 OR NC6)/ES
L50           7 S L46 NOT L47-L49
L51           6 S L50 NOT ETHANOL
L52           1 S L51 AND 2/NR
L53           5 S L51 NOT L52
L54           1 S ETHANOL/CN

     FILE 'HCAPLUS' ENTERED AT 15:44:05 ON 11 MAR 2004
L55           5 S L53
L56          20 S L47
L57         226 S L48
L58           8 S L49
L59         276 S CABERGOLIN# OR DOSTINEX OR GAGASTOP OR SOGILEN# OR CABASER#
L60         306 S L55-L59
L61         180 S L60 AND (PD<=20000816 OR PRD<=20000816 OR AD<=20000816)
L62           3 S L34-L44 AND L60
L63           3 S L45,L62
L64         189 S (L53 OR L47 OR L48 OR L49)(L)THU/RL
L65         100 S L61 AND L64
L66      182676 S L52 OR L54
L67           5 S L65 AND L66
```

```
L68           5 S L61 AND L66
L69           7 S L63,L67,L68
L70         287 S L11 OR L32
L71         188 S L70 AND (PD<=20000816 OR PRD<=20000816 OR AD<=20000816)
L72         199 S (L11 OR L32)(L)THU/RL
L73         109 S L71 AND L72
L74           5 S L73 AND L66
L75           7 S L69,L74
                E TOBACCO/CT
L76       31172 S E3+NT
                E E3+ALL
L77           1 S E8
                E SMOKE/CT
                E E3+ALL
L78       23964 S E15+NT
                E ADDICTION/CT
                E DRUG DEPENDENCE/CT
L79        8707 S E3,E4
                E E3+ALL
L80       13006 S E3+NT
L81        7231 S E8+NT
L82       42741 S E10+NT
                E E10+ALL
L83         362 S E2
L84          10 S L72 AND L76-L83
L85           2 S L75 AND L84
L86           8 S L84 NOT L85
L87           7 S L75,L85
L88         221 S L61,L71
L89          12 S L88 AND (NICOTINE OR TOBACCO OR CIGAR? OR SMOKE OR SMOKING OR
L90           9 S L89 NOT L87
L91           3 S L87 AND L89
L92           7 S L87,L91

     FILE 'REGISTRY' ENTERED AT 15:56:42 ON 11 MAR 2004

     FILE 'HCAPLUS' ENTERED AT 15:58:29 ON 11 MAR 2004

     FILE 'MEDLINE' ENTERED AT 16:03:19 ON 11 MAR 2004
L93         388 S L60
L94         235 S L93 AND PY<=2000
L95           0 S L94 AND L52
L96           0 S L94 AND L54
                E TOBACCO/CT
                E E3+ALL
L97       13333 S E6+NT
L98       77154 S E10+NT OR E11+NT OR E12+NT
                E TOBACCO/CT
                E E4+ALL
L99        6963 S E2+NT
                E TOBACCO/CT
L100       1314 S E13+NT
L101       4550 S E55+NT
                E ALCOHOLISM/CT
L102      47327 S E3+NT
                E E3+AKK
                E E3+ALL
L103       7153 S E15+NT OR E16+NT OR E17+NT OR E18+NT
L104      65642 S E6+NT
                E E5+ALL
L105     136792 S E5+NT
L106      69744 S E75+NT OR E80+NT OR E79+NT OR E77+NT
L107          0 S L94 AND L97-L106
```

L108 19 S L94 AND (SMOK? OR TOBACCO OR NICOTIN? OR ALCOHOL? OR ABUSE OR

=>

↑ irrelevant - false hits